Astera Labs, Inc. (NASDAQ:ALAB) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Astera Labs, Inc. has received an average recommendation of "Moderate Buy" from 18 research firms, with 14 analysts suggesting a buy and 1 issuing a strong buy recommendation.
• The company recently reported earnings of $0.44 per share for the last quarter, exceeding analyst expectations, with a year-over-year revenue growth of 149.5%.
• Insiders sold a significant number of shares recently, with the COO selling 280,000 shares, indicating a 4.82% decrease in their holdings.

Astera Labs, Inc. (NASDAQ:ALAB - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eighteen research firms that are currently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, fourteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $129.1333.

A number of research firms have commented on ALAB. Barclays reiterated an "overweight" rating and issued a $155.00 price objective (up previously from $75.00) on shares of Astera Labs in a report on Thursday, August 7th. Northland Capmk cut shares of Astera Labs from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 22nd. Evercore ISI increased their price target on shares of Astera Labs from $104.00 to $215.00 and gave the company an "outperform" rating in a research note on Wednesday, August 6th. Northland Securities cut shares of Astera Labs from an "outperform" rating to a "market perform" rating and set a $120.00 price target for the company. in a research note on Tuesday, July 22nd. Finally, Stifel Nicolaus set a $145.00 price target on shares of Astera Labs and gave the company a "buy" rating in a research note on Monday, August 4th.

Astera Labs Trading Up 0.4%

ALAB stock opened at $179.20 on Thursday. The company has a market cap of $29.79 billion, a price-to-earnings ratio of 320.00, a PEG ratio of 4.53 and a beta of 1.39. Astera Labs has a 12 month low of $36.85 and a 12 month high of $199.47. The firm has a 50-day moving average of $128.86 and a two-hundred day moving average of $94.43.

Astera Labs (NASDAQ:ALAB - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.33 by $0.11. The company had revenue of $191.93 million during the quarter, compared to the consensus estimate of $172.46 million. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. Astera Labs's quarterly revenue was up 149.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.13 EPS. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. As a group, equities analysts forecast that Astera Labs will post 0.34 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Sanjay Gajendra sold 280,000 shares of the stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $170.02, for a total transaction of $47,605,600.00. Following the completion of the transaction, the chief operating officer owned 5,525,545 shares of the company's stock, valued at approximately $939,453,160.90. This trade represents a 4.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jitendra Mohan sold 152,517 shares of the stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $170.33, for a total transaction of $25,978,220.61. Following the transaction, the chief executive officer directly owned 450,001 shares of the company's stock, valued at $76,648,670.33. The trade was a 25.31% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,205,616 shares of company stock valued at $280,372,731. Company insiders own 12.50% of the company's stock.

Hedge Funds Weigh In On Astera Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALAB. NewEdge Advisors LLC purchased a new position in Astera Labs in the 4th quarter valued at approximately $63,000. Dimensional Fund Advisors LP boosted its position in Astera Labs by 4.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 18,250 shares of the company's stock valued at $2,417,000 after buying an additional 768 shares during the period. MetLife Investment Management LLC boosted its position in Astera Labs by 391.3% in the 4th quarter. MetLife Investment Management LLC now owns 2,137 shares of the company's stock valued at $283,000 after buying an additional 1,702 shares during the period. MML Investors Services LLC purchased a new position in Astera Labs in the 4th quarter valued at approximately $1,401,000. Finally, Tower Research Capital LLC TRC boosted its position in Astera Labs by 84.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,476 shares of the company's stock valued at $460,000 after buying an additional 1,587 shares during the period. Hedge funds and other institutional investors own 60.47% of the company's stock.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.